Oncology

Amgen 2020 Biosimilar Report Provides Market Share, ASP Info

October 14, 2020

Tony Hagen

Article

Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States.

Interview: Understanding the Attraction for PD-1 Inhibitor Biosimilars

October 13, 2020

Tony Hagen

Article

Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.

Report: Specialty Drug Assessment Highlights Biosimilar Progress

October 12, 2020

Skylar Jeremias

Article

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

International Presenters Share Tips on Beefing Up Biosimilar Use

October 9, 2020

Skylar Jeremias

Article

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6, 2020

Skylar Jeremias

Article

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

ASCO Survey Measures COVID-19 Effect on Cancer Treatment

October 5, 2020

Tony Hagen

Article

During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics.

Centus’ Avastin Biosimilar Receives EC Approval

October 1, 2020

Skylar Jeremias

Article

Centus’ Equidacent became Europe’s fourth bevacizumab biosimilar to receive marketing authorization.

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29, 2020

Skylar Jeremias

Article

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Report: Germany Has Not Fully Realized Its Biosimilar Potential

September 29, 2020

Deana Ferreri, PhD

Article

Germany could eke out more gains from biosimilars on top of its already impressive savings, investigators write.

Byvasda Shines in Combination With PD-1 Inhibitor

September 28, 2020

Skylar Jeremias

Article

Trial results demonstrated that Innovent Biologics’ bevacizumab biosimilar was effective in combination therapy with a PD-1 inhibitor in patients with hepatocellular carcinoma.

x